Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 141

Sort by

Sort Order Select

Journal Articles

Bone Marrow-Free Sequencing of M Protein Genes: A Liquid Biopsy Approach in Monoclonal Gammopathies

Alice Nevone, Arian Sadeghi, Giulia Mazzini, Paolo Milani, Silvia Mangiacavalli, Serena Caminito, Francesca Lattarulo, Monica Russo, Giada Panno, Marco Basset, Claudio Salvatore Cartia, Pietro Benvenuti, Martina Nanci, Claudia Bellofiore, Andrea Foli, Giampaolo Merlini, Luca Arcaini, Giovanni O. Palladini, Mario Nuvolone

Blood (2024) 144 (Supplement 1): 6905.

https://doi.org/10.1182/blood-2024-206861

Published: 2024

Journal Articles

Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research

Blood (2024) 144 (Supplement 1): 1927.1.

https://doi.org/10.1182/blood-2024-200529

Published: 2024

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni O. Palladini, Meletios-Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C Minnema, Ashutosh D. Wechalekar, Stavros Golfinopoulos, Nasia Antoniou, Giorgos Psarros, Pieter Sonneveld, Stefan Schonland

Blood (2024) 144 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2024-203254

Published: 2024

Journal Articles

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Blood (2024) 144 (Supplement 1): 891.

https://doi.org/10.1182/blood-2024-205077

Published: 2024

Journal Articles

Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis

Blood (2024) 144 (Supplement 1): 889.

https://doi.org/10.1182/blood-2024-202995

Published: 2024

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C Minnema, Meletios-Athanasios Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj Merzoug, Stavros Golfinopoulos, Nasia Antoniou, Giorgos Psarros, Pieter Sonneveld, Giovanni O. Palladini

Blood (2024) 144 (Supplement 1): 1979.

https://doi.org/10.1182/blood-2024-202932

Published: 2024

Journal Articles

Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population

Eli Muchtar, Susan Geyer, Giampaolo Merlini, Morie A. Gertz

Blood (2024) 144 (7): 790–793.

https://doi.org/10.1182/blood.2024024623

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C Minnema, Meletios A. Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj Merzoug, Elena Papachristou, Kyriaki Manousou, Pieter Sonneveld, Giovanni Palladini

Blood (2023) 142 (Supplement 1): 539.

https://doi.org/10.1182/blood-2023-185811

Published: 2023

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni Palladini, Meletios Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C Minnema, Ashutosh D. Wechalekar, Elena Papachristou, Giorgos Psarros, Pieter Sonneveld, Stefan Schonland

Blood (2023) 142 (Supplement 1): 4779.

https://doi.org/10.1182/blood-2023-185861

Published: 2023

Journal Articles

Light Chain Amyloidosis Plasma Cells Show Specific Chromatin Accessibility and Transcriptome

Blood (2023) 142 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2023-185614

Published: 2023

Journal Articles

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Blood (2023) 142 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2023-190226

Published: 2023

Journal Articles

Daratumumab-Based Regimens Versus Cybord in Newly Diagnosed Patients with AL Amyloidosis and IIIb Cardiac Stage: A Matched Case-Control Study

Claudia Bellofiore, Marco Basset, Pietro Benvenuti, Mario Nuvolone, Andrea Foli, Martina Nanci, Gianluigi Guida, Andrea Attanasio, Giampaolo Merlini, Giovanni Palladini, Paolo Milani

Blood (2023) 142 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2023-184681

Published: 2023

Journal Articles

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashutosh Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini

Blood (2023) 142 (14): 1208–1218.

https://doi.org/10.1182/blood.2022019406

Published: 2023

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni Palladini, Meletios-Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C. Minnema, Ashutosh D. Wechalekar, Sreeja Varghese, Kyriaki Manousou, Pieter Sonneveld, Stefan Schönland

Blood (2022) 140 (Supplement 1): 7294–7296.

https://doi.org/10.1182/blood-2022-169688

Published: 2022

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C. Minnema, Meletios-Athanasios Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj, Sreeja Varghese, Kyriaki Manousou, Pieter Sonneveld, Giovanni Palladini

Blood (2022) 140 (Supplement 1): 1841–1843.

https://doi.org/10.1182/blood-2022-168757

Published: 2022

Journal Articles

Bone Marrow-Free Sequencing of M Protein Genes in Monoclonal Gammopathies

Alice Nevone, Giulia Mazzini, Paolo Milani, Silvia Mangiacavalli, Anna Melati, Giulia Scanavino, Maria Girelli, Serena Caminito, Marco Basset, Claudio Salvatore Cartia, Pietro Benvenuti, Martina Nanci, Claudia Bellofiore, Andrea Foli, Giampaolo Merlini, Luca Arcaini, Giovanni Palladini, Mario Nuvolone

Blood (2022) 140 (Supplement 1): 12431–12433.

https://doi.org/10.1182/blood-2022-168615

Published: 2022

Journal Articles

Predictors of Hematologic Complete Response Achievement and Maintenance in Patients with AL Amyloidosis Treated with Non-Transplant Chemotherapy

Paolo Milani, Claudia Bellofiore, Marco Basset, Andrea Foli, Pietro Benvenuti, Francesca Fabris, Martina Nanci, Mario Nuvolone, Giampaolo Merlini, Giovanni Palladini

Blood (2022) 140 (Supplement 1): 7172–7173.

https://doi.org/10.1182/blood-2022-169614

Published: 2022

Journal Articles

Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival

Marco Basset, Paolo Milani, Andrea Foli, Mario Nuvolone, Pietro Benvenuti, Martina Nanci, Francesca Fabris, Claudia Bellofiore, Giampaolo Merlini, Giovanni Palladini

Blood (2022) 140 (18): 1964–1971.

https://doi.org/10.1182/blood.2022016348

Published: 2022

Includes: Supplemental data

Journal Articles

How I treat AL amyloidosis

Giovanni Palladini, Giampaolo Merlini

Blood (2022) 139 (19): 2918–2930.

https://doi.org/10.1182/blood.2020008737

Published: 2022

Journal Articles

Two-hit strategy for treating AL amyloidosis?

Giampaolo Merlini, Giovanni Palladini

Blood (2021) 138 (25): 2596–2598.

https://doi.org/10.1182/blood.2021013817

Published: 2021

NARROW

Bone Marrow-Free Sequencing of M Protein Genes: A Liquid Biopsy Approach in Monoclonal Gammopathies

Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Light Chain Amyloidosis Plasma Cells Show Specific Chromatin Accessibility and Transcriptome

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Daratumumab-Based Regimens Versus Cybord in Newly Diagnosed Patients with AL Amyloidosis and IIIb Cardiac Stage: A Matched Case-Control Study

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Bone Marrow-Free Sequencing of M Protein Genes in Monoclonal Gammopathies

Predictors of Hematologic Complete Response Achievement and Maintenance in Patients with AL Amyloidosis Treated with Non-Transplant Chemotherapy

Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival

How I treat AL amyloidosis

Two-hit strategy for treating AL amyloidosis?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only